Channel Therapeutics Corporation
CHRO · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7,406 | $0 | $0 | $933 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $194 | $894 |
| Gross Profit | $0 | $0 | -$194 | $467 |
| % Margin | 0% | – | – | 50% |
| R&D Expenses | $145 | $515 | $194 | $285 |
| G&A Expenses | $0 | $2,716 | $1,640 | $1,540 |
| SG&A Expenses | $19,628 | $2,716 | $1,640 | $1,540 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$12,367 | $0 | $0 | -$894 |
| Operating Expenses | $7,406 | $3,230 | $1,834 | $931 |
| Operating Income | $0 | -$3,230 | -$1,834 | -$1,825 |
| % Margin | 0% | – | – | -195.6% |
| Other Income/Exp. Net | $0 | -$219 | -$134 | -$102 |
| Pre-Tax Income | -$16,703 | -$3,449 | -$1,968 | -$1,927 |
| Tax Expense | -$465 | $0 | $0 | $0 |
| Net Income | -$16,238 | -$3,449 | -$1,968 | -$1,927 |
| % Margin | -219.3% | – | – | -206.5% |
| EPS | -5.3 | -5.38 | -0.32 | -0.34 |
| % Growth | 1.5% | -1,581.2% | 5.9% | – |
| EPS Diluted | -5.3 | -5.38 | -0.32 | -0.34 |
| Weighted Avg Shares Out | 3,061 | 641 | 6,128 | 5,683 |
| Weighted Avg Shares Out Dil | 3,061 | 641 | 6,128 | 5,683 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,346 | $219 | $134 | $108 |
| Depreciation & Amortization | $974 | $0 | $1,834 | -$1,160 |
| EBITDA | -$14,383 | -$3,230 | -$0 | -$2,218 |
| % Margin | -194.2% | – | – | -237.6% |